Navigation Links
Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
Date:9/4/2007

lower blood pressure, explained Dr. Anushka Patel, of The George Institute and the ADVANCE Study Director. However, the addition of the fixed combination of perindopril and indapamide reduced the risk of death from any cause by 14% and the risk of death from cardiovascular disease by 18%. Over 5 years, this treatment would prevent one death among every 80 patients treated.

The results clearly demonstrate that we have the tools to blunt the impact of the global diabetes epidemic facing rich and poor countries alike. But concerted action is urgently required to ensure that patients with diabetes are identified and provided with treatments proven to improve important outcomes like survival, added Professor John Chalmers, the author of international guidelines for the treatment of high blood pressure and chairman of the study management group.


'/>"/>

Contact: Janet Hall
janethall@bigpond.com
61-411-187-808
Research Australia
Source:Eurekalert

1

GOOD

Page: 1 2

Related medicine news :

1. International community warns India on HIV situation
2. Key step forward on International Health Rules
3. ICMR along with other International Research organisation with drug development for Neglected Diseases
4. International Osteoporosis Research Centre To Be Started In India.
5. Indian hospitals require International Accreditation
6. International Conference On Malaria - Laveran To Genomics
7. Delhi To Host International Women’s Congress From Nov 2
8. International conference on Ayurveda to be held on Kerala
9. International Teleradiology: The Future Of Radiologic Diagnosis
10. John Mendelsohn M.D, chosen for an International Award
11. Thailand To Procure Botulism Antitoxin Internationally
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Study shows ultrasound and tPA effective for stroke 2Health News:Lifetime Caps Bill Introduced 2Health News:Providence Service Corporation California Subsidiary Awarded $1.5 Million Contract Under State's Mental Health Services Act 2Health News:Frost & Sullivan Recognizes WCC for Its Unique Multimodal Platform 2Health News:Frost & Sullivan Recognizes WCC for Its Unique Multimodal Platform 3Health News:Frost & Sullivan Recognizes WCC for Its Unique Multimodal Platform 4Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 2Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 3Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 4Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 5Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 6Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 7Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 8Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 9Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 10Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 11Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 12Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 13Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 14Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 15Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 16Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 17Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 18Health News:Musculoskeletal Clinical Regulatory Advisers, LLC Announces Signing of its 100th Client 2
Breaking Medicine Technology:BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4Shanghai ChemPartner Is Pleased to be Part of Agios' Groundbreaking Cancer Research 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 3Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 4Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 5Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 6Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 7Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 8Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 9Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 10Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 11Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 12Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 13Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6130 1Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6130 2Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6130 3Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6130 4Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6130 5Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6130 6Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6130 7Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6130 8Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6130 9Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6130 10Sigma Aldrich Enters Distribution Agreement With Stemgent Inc to Offer Lentivirus Based Gene Delivery Products for Regenerative Medicine and Stem Ce 6123 1Sigma Aldrich Enters Distribution Agreement With Stemgent Inc to Offer Lentivirus Based Gene Delivery Products for Regenerative Medicine and Stem Ce 6123 2Sigma Aldrich Enters Distribution Agreement With Stemgent Inc to Offer Lentivirus Based Gene Delivery Products for Regenerative Medicine and Stem Ce 6123 3Climate studies to benefit from 12 years of satellite aerosol data 61062 1Climate studies to benefit from 12 years of satellite aerosol data 61062 2